List of Excipients in Branded Drug TYBLUME

« Back to Dashboard

TYBLUME Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

TYBLUME is a chewable combined oral contraceptive containing levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg. Its commercial differentiation depends on delivery format, taste, swallowability, and adherence rather than novel active ingredients. The excipient platform is relatively conventional, leaving opportunities in sugar reduction, allergen positioning, flavor performance, dose uniformity, and patient-support packaging. The principal regulatory pathway for competitors is an abbreviated new drug application, with formulation changes constrained by bioequivalence, pharmaceutical equivalence, product quality, and palatability requirements.[1]

What is TYBLUME and how does its formulation work?

TYBLUME is a 28-day oral contraceptive regimen with 24 active chewable tablets and four inert tablets. Each active tablet contains levonorgestrel and ethinyl estradiol. The chewable format allows administration with or without water, which targets patients who have difficulty swallowing conventional tablets or prefer a non-swallow dosage form.[1]

TYBLUME product profile

Attribute	TYBLUME
Active ingredients	Levonorgestrel 0.1 mg; ethinyl estradiol 0.02 mg
Dosage form	Chewable tablet
Regimen	24 active tablets followed by four inert tablets
Therapeutic category	Combined hormonal oral contraceptive
Administration	Chew or swallow; water is not required
Route	Oral
Sponsor and marketer	Exeltis USA, Inc.
FDA status	Prescription drug approved through an NDA pathway
Primary differentiation	Chewability, portability, and administration without water

The dosage form is particularly relevant for adolescents, young adults, patients with dysphagia, travelers, and users who have difficulty maintaining daily routines involving water or meals.

What excipients are used in TYBLUME?

The TYBLUME prescribing information identifies a conventional solid-dose excipient system that supports compression, tablet integrity, flow, lubrication, palatability, and mouthfeel.[1]

TYBLUME excipient functions

Excipient	Likely formulation function
Lactose monohydrate	Diluent and tablet-bulk agent
Microcrystalline cellulose	Diluent, dry binder, and compression aid
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Sucralose	High-intensity sweetener
Flavoring	Taste and sensory masking

The formulation has two important design implications. First, the active doses are low, so content uniformity and blend control are critical. Second, the tablet must perform as both a solid oral dosage form and a palatable chewable product. Conventional excipients that work well in swallowed tablets can produce unacceptable grittiness, chalkiness, aftertaste, or lubricant perception when chewed.

Why is lactose commercially relevant?

Lactose is widely used and generally cost-efficient, but it creates positioning constraints for products marketed to patients seeking lactose-free or excipient-minimized formulations. A competitor using mannitol, sorbitol, isomalt, or a co-processed polyol system could develop a different mouthfeel and allergen profile.

The commercial opportunity is not necessarily a clinical advantage. A lactose-free claim would require appropriate formulation controls, labeling review, and market evidence that patients value the distinction. Sugar-free positioning is also not equivalent to lactose-free positioning because lactose is a milk-derived disaccharide, while sucralose is the identified sweetener.

What formulation patents protect TYBLUME?

Public product information identifies the TYBLUME formulation and dosage form, but commercial analysis should distinguish three different forms of protection:

1. Patents covering the active contraceptive combination or use.
2. Patents covering a chewable oral contraceptive dosage form.
3. Patents covering specific excipient combinations, taste-masking systems, manufacturing processes, or packaging.

The commercial value of an excipient patent depends on claim scope. A claim limited to a narrow sweetener, flavor, binder, or compression range may be easier to design around than a claim covering the product's overall chewable performance or a defined dissolution and palatability profile.

What patent claims would matter most?

The strongest potential formulation claims would typically address:

• A defined ratio of levonorgestrel and ethinyl estradiol with a specified excipient matrix.
• A chewable tablet meeting dissolution, hardness, friability, and sensory limits.
• A low-dose blend with defined content-uniformity performance.
• A taste-masking system that suppresses hormonal bitterness.
• A tablet that can be chewed or swallowed without water.
• A manufacturing process that prevents segregation of low-dose active ingredients.
• A calendar blister package that reduces missed-dose risk.

Exact patent protection should be assessed against the FDA Orange Book, USPTO records, and the sponsor's patent portfolio. The label alone does not establish whether a patent is listed for the product.[2]

What is the Orange Book status of TYBLUME?

TYBLUME is an approved prescription drug, but Orange Book status must be evaluated using the current FDA listing rather than relying on marketing materials or third-party databases.[2] Relevant questions include whether the approved product has listed patents, whether any listed patents are method-of-use or formulation patents, and whether the listing creates a Paragraph IV certification opportunity for an ANDA applicant.

For a generic applicant, the strategic distinction is material:

Regulatory issue	Commercial effect
No listed patent blocking approval	ANDA timing is driven mainly by regulatory review and exclusivity
Formulation patent listed	Applicant may need a Paragraph IV certification or wait for expiry
Method-of-use patent listed	A section viii carve-out may be possible if the protected use can be omitted
Product-specific exclusivity	May delay ANDA approval even without a blocking patent
Chewable dosage-form complexity	Can increase development and bioequivalence risk

TYBLUME is a small-molecule combination product, not a biologic. Biosimilar pathways do not apply. Competitive entry would generally proceed through an ANDA or, for a materially different product, a new drug application.

When does TYBLUME lose exclusivity?

TYBLUME's market exclusivity is determined by the combination of FDA regulatory exclusivity, any listed patent terms, and enforceable intellectual-property rights. A reliable commercial forecast requires the current FDA approval record and patent register because the nominal approval date alone does not determine generic launch timing.

What generic entry risks exist?

Generic entry risk is moderate from a technical perspective and potentially high from a price-competition perspective.

The active ingredients are established and the dosage strengths are well characterized. A competitor can use the same active combination and pursue pharmaceutical equivalence. The more difficult development issues are:

• Matching the chewable tablet's sensory profile.
• Demonstrating acceptable disintegration and dissolution.
• Achieving uniform distribution of low-dose hormones.
• Controlling tablet friability without creating a hard, unpleasant chew.
• Reproducing the 24-active/4-inert regimen and packaging.
• Establishing bioequivalence under the applicable FDA requirements.

A generic applicant does not necessarily need to duplicate every inactive ingredient. FDA regulations permit differences in excipients when the product remains pharmaceutically equivalent and meets applicable safety, quality, and performance standards.[3]

How can competitors differentiate through excipients?

The most credible opportunities fall into four formulation strategies.

1. Lactose-free and polyol-based formulations

Replacing lactose with mannitol, isomalt, or another directly compressible diluent could support lactose-free positioning. Mannitol can provide a cooling mouthfeel, while isomalt can offer lower hygroscopicity than some sugar alcohols. The tradeoffs include cost, tablet hardness, friability, moisture behavior, and gastrointestinal tolerance.

2. Improved taste masking

Hormonal actives can produce bitterness and persistent aftertaste. Competitors could use:

• Ion-exchange resins.
• Polymer coatings.
• Cyclodextrin complexes.
• Encapsulation.
• Alternative flavors with longer-lasting masking.
• Layered or granulated active systems.

A taste-masking approach must preserve rapid and consistent release. Excessive coating can alter dissolution and create regulatory comparability problems.

3. Better mouthfeel

Chewable tablets can fail commercially because of grittiness, chalkiness, excessive hardness, or poor saliva dispersion. Co-processed excipients may improve compressibility and reduce the need for high lubricant levels. A smoother mouthfeel may be more commercially important than a new flavor.

4. Excipient systems designed for moisture resistance

Contraceptive products are commonly carried in handbags, backpacks, and travel cases. A formulation with improved moisture resistance could reduce tablet softening, sticking, discoloration, and package degradation. Aluminum blister packaging, high-barrier films, and desiccant-supported secondary packaging can complement the formulation.

What manufacturing and intellectual-property barriers affect TYBLUME?

Low-dose combination tablets create a high content-uniformity burden. Levonorgestrel and ethinyl estradiol must be distributed consistently despite their small quantities relative to the excipient mass. Manufacturing controls may include geometric dilution, ordered mixing, granulation, segregation testing, and in-process assay sampling.

The principal manufacturing risks are:

Risk	Potential consequence
Blend segregation	Failed content-uniformity testing
Excess magnesium stearate	Slower dissolution and poor tablet bonding
Insufficient lubrication	Sticking and punch damage
Excessive tablet hardness	Poor chewability
High friability	Package breakage and dose loss
Flavor volatility	Loss of sensory performance during shelf life
Moisture uptake	Texture change and stability failures

Process know-how can create a meaningful barrier even where composition-of-matter protection is absent. However, process protection is generally less effective against a competitor using a different manufacturing route unless the claims cover the resulting product or a necessary process step.

How does TYBLUME compare with conventional oral contraceptives?

Commercial attribute	TYBLUME	Conventional swallowed tablet
Water required	No	Usually taken with water
Swallowability	Can be chewed	Requires swallowing
Sensory performance	Critical	Usually secondary
Excipient differentiation	High	Moderate
Manufacturing complexity	Higher	Lower
Packaging opportunity	High	Moderate
Generic substitution risk	Meaningful	Usually high
Patient adherence proposition	Convenience and swallowability	Familiarity and broad availability

TYBLUME's advantage is dosage-form convenience, not a new contraceptive mechanism. A competitor could erode that advantage with a lower-cost chewable generic, a dissolving tablet, an orally disintegrating tablet, or a better-tasting formulation.

What commercial opportunities exist for TYBLUME?

The strongest opportunities are adjacent to formulation and adherence.

Patient segments

Potential target segments include:

• Adolescents starting oral contraception.
• Patients with swallowing difficulty.
• Users who frequently travel or lack reliable access to water.
• Patients who prefer chewable medicines.
• Users who discontinue conventional pills because of administration inconvenience.

The product is less differentiated for patients who already prefer standard swallowed tablets and are highly price sensitive.

Packaging and adherence programs

A calendar blister with clear active and inert tablet separation could reduce dosing errors. Commercial extensions could include:

• Starter packs with visual day-of-week labeling.
• Compact travel packaging.
• Refill reminders.
• QR-linked adherence education.
• Pharmacy counseling materials.
• Co-branded telehealth fulfillment.

These initiatives do not create patent exclusivity, but they can improve persistence and reduce substitution where patients value convenience.

Licensing opportunities

Potential licensing targets include:

• Co-processed excipient suppliers.
• Taste-masking technology companies.
• High-barrier blister-packaging manufacturers.
• Contract manufacturers with chewable-tablet expertise.
• Digital adherence and reproductive-health platforms.
• Regional pharmaceutical companies seeking a differentiated contraceptive product.

A licensing deal would have the greatest strategic value if it produced a protected formulation, a materially better sensory profile, or access to a new geographic market. A basic excipient substitution without measurable patient or manufacturing benefit is unlikely to justify substantial royalties.

What is the revenue exposure and competitive outlook?

Brand-level TYBLUME revenue is not generally disclosed as a separate public line item. The commercial exposure is therefore best assessed through prescription volume, formulary position, refill persistence, payer coverage, and generic timing rather than reported product revenue.

The revenue risk profile has three stages:

1. Early commercialization: differentiation depends on awareness, access, and patient acceptance of chewable contraception.
2. Pre-generic maturity: the brand can defend pricing if patients value taste, convenience, and packaging.
3. Generic entry: price erosion can be rapid because the active ingredients are established and therapeutic substitution is straightforward.

A durable premium requires evidence that patients remain on TYBLUME longer, prefer its sensory attributes, or experience fewer administration failures than with swallowed tablets. Without that evidence, excipient differentiation may support marketing but not sustained pricing power.

Key Takeaways

• TYBLUME is a levonorgestrel/ethinyl estradiol chewable oral contraceptive with 24 active and four inert tablets.
• Its excipient system supports compression, disintegration, lubrication, sweetness, and flavor masking.
• The main formulation opportunity is improved sensory performance, not a new pharmacologic effect.
• Lactose-free, sugar-free, smoother, and more moisture-resistant products are credible competitive concepts.
• Generic applicants can potentially vary excipients if they satisfy pharmaceutical-equivalence and bioequivalence requirements.
• Low-dose content uniformity, chewability, dissolution, and taste are the main technical barriers.
• TYBLUME is a small-molecule product, so biosimilar competition is not relevant.
• Patent and exclusivity conclusions require current Orange Book and USPTO review; the label does not establish the complete patent estate.
• No separate public TYBLUME revenue figure is generally available, making prescription and refill data more useful for exposure analysis.
• The strongest licensing opportunities involve taste masking, co-processed excipients, high-barrier packaging, and adherence technology.

FAQs

Can TYBLUME be reformulated without lactose?

Yes. A competitor could evaluate mannitol, isomalt, or another directly compressible diluent. The replacement would need to preserve tablet quality, dissolution, stability, and bioequivalence.

Does TYBLUME have an advantage over oral contraceptive gummies?

Not necessarily. TYBLUME is a regulated chewable tablet with defined active doses. A gummy product would face different stability, dose-uniformity, preservative, moisture, and manufacturing requirements.

Could a generic use a different flavor from TYBLUME?

Potentially. Flavoring is generally not required to be identical if the generic meets applicable pharmaceutical-equivalence, quality, safety, and performance standards. A different flavor could create a sensory advantage or disadvantage.

Is a chewable contraceptive easier to develop than an orally disintegrating tablet?

No. A chewable tablet must balance hardness, friability, taste, mouthfeel, and release. An orally disintegrating tablet introduces separate risks involving rapid disintegration, moisture sensitivity, packaging, and dose uniformity.

Can TYBLUME's packaging create meaningful commercial protection?

Packaging alone rarely blocks generic approval, but it can support adherence, reduce handling failures, improve brand recognition, and strengthen patient retention. Patent value depends on whether the packaging claims solve a specific technical problem and withstand design-around strategies.

References

1. Exeltis USA, Inc. (n.d.). TYBLUME prescribing information: Levonorgestrel and ethinyl estradiol chewable tablets. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.